Ovarian Stimulation in IVF: Protocols, Timeline, and Safety

Key Takeaways

Ovarian stimulation encourages a cohort of follicles to develop using tailored gonadotropin doses over approximately 8 to 14 days. Protocol choice depends on ovarian reserve, age, and health history to optimize mature egg yield while minimizing the risk of ovarian hyperstimulation syndrome (OHSS). Modern GnRH antagonist protocols and agonist triggers provide effective follicular recruitment with enhanced safety.

Key evidence: 2025 ESHRE Guideline: Ovarian Stimulation for IVF/ICSI · ASRM Practice Committee: Prevention of Moderate and Severe OHSS · Cochrane Review: GnRH Antagonists vs Agonists in IVF

Understanding Ovarian Stimulation in IVF

Ovarian stimulation is the initial medical stage of an in vitro fertilization (IVF) cycle. Its biological role is to support the concurrent development of multiple ovarian follicles within a single cycle.

In a spontaneous natural cycle, the pituitary gland secretes follicle-stimulating hormone (FSH) in amounts sufficient for only one dominant follicle to reach ovulation. The other resting follicles recruited during that monthly wave undergo natural cellular regression, known as atresia. During IVF, daily gonadotropin medications support this existing monthly cohort, enabling the embryology team to collect, fertilize, and evaluate multiple eggs.

Obtaining several oocytes provides the laboratory with a cohort for fertilization and blastocyst culture. Because not every retrieved egg is mature, and not every fertilized egg develops into a viable embryo, having a reasonable number of mature eggs supports cumulative pregnancy chances across fresh and frozen transfers.

Medication requirements vary widely between individuals. As a result, gonadotropin doses are calculated individually and adjusted throughout the cycle rather than administered as a fixed formula.

Dr. Aksoy’s Approach:
Dr. Aksoy emphasizes that controlled efficiency and safety take priority over chasing maximum oocyte numbers. In clinical practice, the aim is to obtain a well-matured cohort of oocytes while keeping medication doses proportionate, minimizing patient discomfort, and actively managing the risk of ovarian hyperstimulation.

Why Stimulation Protocols Differ

No single protocol is suitable for every patient. A stimulation regimen that produces a safe and moderate response in one individual may lead to an inadequate response or significant over-response in another.

When tailoring a stimulation plan, fertility specialists evaluate biomarkers and patient characteristics outlined in the 2025 ESHRE Guideline on Ovarian Stimulation for IVF/ICSI:

• Ovarian reserve markers: Serum anti-Müllerian hormone (AMH) and baseline antral follicle count (AFC) assessed by transvaginal ultrasound.
• Age and reproductive history: Age correlates with chromosomal competency in oocytes and expected responsiveness to gonadotropins.
• Underlying diagnosis: Conditions such as polycystic ovary syndrome (PCOS) require conservative starting doses due to higher follicular sensitivity, whereas diminished reserve may warrant specific dosing strategies.
• Body mass index (BMI): Influences medication distribution and metabolic clearance.
• Prior cycle response: Details from previous IVF attempts help guide starting doses and trigger choices.

Common Protocol Types

1. GnRH Antagonist Protocol:
   The primary first-line protocol recommended by international guidelines for most IVF patients. Gonadotropin injections start on day 2 or 3 of the menstrual cycle. A GnRH antagonist (such as cetrorelix or ganirelix) is introduced—frequently on day 5 or 6 (fixed protocol, favored in ESHRE guidelines) or when lead follicles reach 12–14 mm (flexible protocol)—to prevent an untimely luteinizing hormone (LH) surge. Cochrane systematic reviews show comparable live birth rates to agonist regimens alongside a lower incidence of ovarian hyperstimulation.

2. Long GnRH Agonist Protocol:
   Involves administering a GnRH agonist starting in the mid-luteal phase of the preceding cycle to achieve pituitary down-regulation before gonadotropins begin. While less frequently used today due to longer treatment duration and higher OHSS risk, it remains an option in selected clinical settings, such as specific presentations of endometriosis or adenomyosis, or when precise cycle scheduling is necessary.

3. Mild or Low-Dose Stimulation:
   Uses lower gonadotropin doses, sometimes combined with oral agents such as letrozole. This approach is considered in selected predicted poor responders where higher medication doses do not increase mature egg numbers, or for patients seeking a less intensive medical regimen.

The Stimulation Timeline: Typical Stages

An ovarian stimulation phase generally lasts between 8 and 14 days before egg retrieval.

Cycle Days 2–3         Days 3–7                Days 6–12               Trigger Day             34–36h Later
[ Baseline Scan ] ───> [ Gonadotropins Start ] ──> [ Antagonist Added ] ───> [ Maturation Trigger ] ──> [ Egg Retrieval ]
   AFC & Hormones        Daily Injections         Monitoring Scans         hCG or Agonist         Minor Procedure

1. Baseline Assessment (Cycle Days 2–3)

Before starting medications, a baseline transvaginal ultrasound confirms that ovaries are quiet, checks for residual functional cysts, and evaluates the resting antral follicle count. Baseline estradiol ($E_2$) and progesterone levels are measured when indicated.

2. Gonadotropin Injections (Days 3–7)

Daily subcutaneous injections of follicle-stimulating hormone (recombinant FSH or human menopausal gonadotropin, hMG) begin. Injections are typically given once daily in the abdomen around the same time each evening.

3. Monitoring Visits (Days 6–12)

Starting around day 5 or 6 of stimulation, clinic visits occur every 2 to 3 days. Transvaginal ultrasound tracks follicle growth, which typically averages 1.5 to 2 mm per day, while blood tests monitor estradiol levels. Dosages may be adjusted based on follicle growth patterns.

4. Preventing an Early LH Surge

In an antagonist protocol, the antagonist is added alongside FSH once the predetermined day (often day 5 or 6) or follicle size threshold is reached, protecting the eggs from premature release.

5. Final Maturation Trigger

When a sufficient cohort of lead follicles reaches mature size (commonly $\ge 17\text{—}18\text{ mm}$ in diameter, interpreted in the context of the overall follicular cohort), the trigger injection is scheduled. This medication completes the final meiotic maturation of the oocytes. Depending on individual hyperstimulation risk, the trigger may be human chorionic gonadotropin (hCG), a GnRH agonist (such as triptorelin), or a dual trigger combining both.

6. Timed Egg Retrieval

Oocyte collection is scheduled approximately 34 to 36 hours after the trigger shot, before spontaneous ovulation occurs. The procedure is performed transvaginally under ultrasound guidance with conscious sedation or anesthesia, typically taking 15 to 20 minutes.

Oocyte Yield: Fresh Outcomes, Cumulative Potential, and Safety

The relationship between egg number and IVF success involves distinct considerations for fresh embryo transfers versus cumulative outcomes across all frozen transfers.

Early large-scale registry analyses, such as Sunkara et al. (2011), demonstrated that in fresh transfer cycles, live birth rates rise with oocyte yield up to approximately 15 eggs, beyond which fresh outcomes plateau while hyperstimulation risks rise.

In contrast, modern analyses examining cumulative live birth rates—which include fresh transfers and all subsequent frozen-thawed embryo transfers from a single stimulation cycle—show that cumulative success continues to rise with higher oocyte yields, particularly in younger women (Law et al., 2019; 2025 pooled analysis).

Achieving high egg numbers is not without trade-offs. In some high-response cycles, a premature late-follicular progesterone rise may affect endometrial synchrony with the developing embryo; this is one reason clinicians may discuss a freeze-all approach (ESHRE 2025 guideline). The decision remains individual and depends on the full clinical picture.

Side Effects and Ovarian Hyperstimulation Syndrome (OHSS)

Most patients experience mild, temporary sensations during stimulation as ovaries enlarge:

• Mild lower abdominal fullness or pelvic pressure
• Moderate bloating
• Breast tenderness and hormonal mood fluctuations
• Minor local redness or bruising at injection sites

Preventing and Managing OHSS

Ovarian Hyperstimulation Syndrome (OHSS) occurs when ovaries over-respond to stimulation, releasing vasoactive mediators such as vascular endothelial growth factor (VEGF) that increase vascular permeability. Historically, moderate-to-severe OHSS occurred in roughly 1% to 5% of IVF cycles, though modern preventive strategies have meaningfully lowered this incidence (ASRM Practice Committee Guideline):

• GnRH Agonist Trigger: In antagonist cycles with high response or in patients with PCOS, replacing hCG with a GnRH agonist trigger produces a shorter LH surge, substantially lowering the risk of early-onset OHSS.
• Elective Freeze-All Strategy: By cryopreserving all blastocysts and deferring transfer, patients avoid pregnancy-derived hCG, which is the main driver of severe late-onset OHSS.
• Dopamine Agonists (Cabergoline): Prescribed selectively in patients identified as high risk around the time of retrieval to reduce vascular permeability.

Warning Signs Requiring Prompt Medical Review

While mild bloating is expected, contact your clinical team promptly if you experience:

• Rapidly worsening abdominal distension or severe pain
• Persistent nausea or vomiting preventing fluid intake
• Noticeable shortness of breath or discomfort when breathing deeply
• Sudden weight gain exceeding 1 kg (2.2 lbs) in 24 hours
• Significantly reduced or dark, concentrated urination

Practical Considerations During Stimulation

1. Follow Injection Instructions: Administer medications within the general daily timeframe recommended by your clinic to maintain consistent hormone levels.
2. Review Storage Requirements: Check individual packaging for storage conditions (some gonadotropins require refrigeration between 2°C and 8°C, while others can be kept at controlled room temperature after initial use).
3. Adjust Physical Activity: As follicles grow and ovaries enlarge, high-impact workouts, heavy lifting, and rapid twisting exercises should be avoided to minimize the risk of ovarian torsion.
4. Hydration and Nutrition: Drink adequate fluids and maintain balanced nutrition with adequate dietary fiber to support digestion and comfort.
5. Maintain Communication: Contact your clinic coordinator whenever questions arise. Adjusting doses based on ultrasound and laboratory findings is a standard aspect of individualized care.

Related Reading

• IVF Protocols and Medications: How Doctors Choose a Plan
• How Many Eggs Are Usually Enough for IVF?
• Egg Retrieval Pain Control: Sedation, Anesthesia, and What to Expect

Frequently Asked Questions

Does ovarian stimulation deplete future egg reserve or bring on earlier menopause?

In each menstrual cycle, a group of immature resting follicles is naturally recruited; in an unmedicated cycle, all but one of these follicles undergo atresia and are lost. Stimulation medications provide hormonal support to allow follicles from that current monthly group to develop. It does not draw from future ovarian reserves or accelerate the onset of menopause.

What happens if follicles grow at different rates?

Follicular growth is frequently asynchronous. Clinical teams monitor the cohort and schedule the trigger when the majority of lead follicles reach appropriate mature diameters, balancing the yield of mature oocytes against the risk of over-maturing the earliest follicles.

Can an IVF stimulation cycle be adjusted or cancelled?

Yes. Stimulation is dynamic. Dosages are adjusted based on individual response. If response is significantly below or above safe parameters, the team may modify medication doses, alter the trigger plan, or occasionally cancel and reschedule with a refined protocol.

How are daily fertility injections generally tolerated?

Most patients find daily subcutaneous injections manageable. Medications are administered with fine micro-needles into the superficial abdominal tissue, and mild local redness or brief stinging typically resolves quickly.

Sources

• ESHRE Guideline Group on Ovarian Stimulation for IVF/ICSI. (2025). Ovarian stimulation for IVF/ICSI: Guideline of the European Society of Human Reproduction and Embryology. ESHRE Guideline
• Practice Committee of the American Society for Reproductive Medicine. (2024). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility, 121(3), 424-439. ASRM Practice Guidance
• Al-Inany, H. G., Youssef, M. A., Ayeleke, R. O., Brown, J., Lam, W. S., & Broekmans, F. J. (2016). Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database of Systematic Reviews, 4, CD001750. PubMed: 27532395
• Sunkara, S. K., Rittenberg, V., Raine-Fenning, N., Bhattacharya, S., Zamora, J., & Coomarasamy, A. (2011). Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Human Reproduction, 26(7), 1768-1774. PubMed: 21558332
• Law, Y. J., Zhang, N., Gordon, C. S., et al. (2019). Cumulative live birth rates following in vitro fertilization: a realistic prediction model. Human Reproduction, 34(9), 1778-1787. Human Reproduction
• StatPearls Publishing. (2023). Ovarian Hyperstimulation Syndrome. NCBI Bookshelf: NBK430792

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed · ORCID · LinkedIn

Read full profile → Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.